Peripherally Restricted CB1 Receptor Inverse Agonist JD5037 Treatment Exacerbates Liver Injury in MDR2-Deficient Mice

Jenny Chen,Fengyuan Li,Jiyeon Lee,Md Manirujjaman,Lihua Zhang,Zhao-Hui Song,Craig McClain,Wenke Feng

DOI: https://doi.org/10.3390/cells13131101

IF: 6

2024-06-26

Cells

Abstract:Previous research highlighted the involvement of the cannabinoid CB1 receptor in regulating the physiology of hepatocytes and hepatic stellate cells. The inhibition of the CB1 receptor via peripherally restricted CB1 receptor inverse agonist JD5037 has shown promise in inhibiting liver fibrosis in mice treated with CCl4. However, its efficacy in phospholipid transporter-deficiency-induced liver fibrosis remains uncertain. In this study, we investigated the effectiveness of JD5037 in Mdr2−/− mice. Mdr2 (Abcb4) is a mouse ortholog of the human MDR3 (ABCB4) gene encoding for the canalicular phospholipid transporter. Genetic disruption of the Mdr2 gene in mice causes a complete absence of phosphatidylcholine from bile, leading to liver injury and fibrosis. Mdr2−/− mice develop spontaneous fibrosis during growth. JD5037 was orally administered to the mice for four weeks starting at eight weeks of age. Liver fibrosis, bile acid levels, inflammation, and injury were assessed. Additionally, JD5037 was administered to three-week-old mice to evaluate its preventive effects on fibrosis development. Our findings corroborate previous observations regarding global CB1 receptor inverse agonists. Four weeks of JD5037 treatment in eight-week-old Mdr2−/− mice with established fibrosis led to reduced body weight gains. However, contrary to expectations, JD5037 significantly exacerbated liver injury, evidenced by elevated serum ALT and ALP levels and exacerbated liver histology. Notably, JD5037-treated Mdr2−/− mice exhibited significantly heightened serum bile acid levels. Furthermore, JD5037 treatment intensified liver fibrosis, increased fibrogenic gene expression, stimulated ductular reaction, and upregulated hepatic proinflammatory cytokines. Importantly, JD5037 failed to prevent liver fibrosis formation in three-week-old Mdr2−/− mice. In summary, our study reveals the exacerbating effect of JD5037 on liver fibrosis in genetically MDR2-deficient mice. These findings underscore the need for caution in the use of peripherally restricted CB1R inverse agonists for liver fibrosis treatment, particularly in cases of dysfunctional hepatic phospholipid transporter.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the therapeutic effect of the peripherally - restricted CB1 receptor inverse agonist JD5037 on liver fibrosis in MDR2 - deficient mice (Mdr2−/− mice). Specifically, the researchers hope to verify through experiments whether JD5037 can reduce or prevent liver fibrosis caused by phospholipid transporter deficiency.

### Background information:
- **CB1 receptor**: The CB1 receptor is part of the endogenous cannabinoid system and is mainly distributed in the central nervous system and peripheral tissues such as the liver. The CB1 receptor plays an important role in regulating inflammation and fibrosis processes.
- **Mdr2−/− mice**: This is a gene - knockout mouse model lacking the Mdr2 gene encoding the bile phospholipid transporter. These mice will spontaneously develop liver fibrosis because the lack of phospholipids in bile leads to cholestasis and liver injury.
- **JD5037**: This is a peripherally - restricted CB1 receptor inverse agonist that cannot cross the blood - brain barrier and therefore does not cause side effects in the central nervous system. Previous studies have shown that JD5037 effectively reduces liver fibrosis in the CCl4 - induced liver fibrosis model.

### Research purposes:
- **Evaluate the efficacy of JD5037 in Mdr2−/− mice**: The researchers hope to understand whether JD5037 can reduce established liver fibrosis in MDR2 - deficient mice or prevent the development of liver fibrosis.
- **Explore potential mechanisms**: By detecting liver enzyme levels, inflammation markers, fibrosis - related gene expression, and bile acid levels and other indicators, the researchers hope to reveal the mechanism of action of JD5037 in Mdr2−/− mice.

### Experimental design:
- **Animal model**: Use 8 - week - old and 3 - week - old Mdr2−/− male mice.
- **Treatment method**: 8 - week - old mice were orally administered JD5037 (3 mg/kg body weight) once every two days for 4 weeks; 3 - week - old mice were orally administered JD5037 once a week for 5 weeks.
- **Control group**: Mice treated with normal saline were used as controls.

### Main findings:
- **Exacerbated liver injury**: After JD5037 treatment, the levels of liver enzymes (ALT and ALP) in Mdr2−/− mice were significantly increased, indicating exacerbated liver injury.
- **Aggravated fibrosis**: After JD5037 treatment, the degree of liver fibrosis in Mdr2−/− mice increased, manifested as increased fiber deposition under Sirius red staining, increased hepatic hydroxyproline content, and up - regulated expression of fibrosis - related genes (such as Col1a1, Timp1, Tgfb1, and Acta2).
- **Increased bile acid levels**: After JD5037 treatment, the serum bile acid levels in Mdr2−/− mice were significantly increased, but there was no significant change in the intrahepatic bile acid levels.
- **Poor preventive effect**: Long - term JD5037 treatment failed to prevent the development of liver fibrosis in 3 - week - old Mdr2−/− mice, but instead exacerbated liver injury and fibrosis.

### Conclusion:
This study found that under the action of the peripherally - restricted CB1 receptor inverse agonist, JD5037 not only failed to reduce or prevent liver fibrosis in Mdr2−/− mice, but also exacerbated liver injury and fibrosis. These results suggest that in the case of phospholipid transporter dysfunction, caution is required when using peripherally - restricted CB1 receptor inverse agonists to treat liver fibrosis, and further research on its potential mechanisms is needed.